Press Release
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
China Medical System (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.
Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.
Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.
CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.
More information about Vecantoxatug and Tetanus
Vecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.
Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].
C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, – tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)₂), and human tetanus immunoglobulin (HTIG) – face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.
More information about Silevimig and Rabies
Silevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.
In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.
Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].
Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.
About GENRIX BIO
Genrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.
Reference:
- China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.001
- Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People’s Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.001
- Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
- Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.004
- Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Charles Wierdsma of Colorado – Why Permitting Discipline and Clear Documentation Reduce Renovation Risk
Sarasota, Florida, 14th January 2026, ZEX PR WIRE, For many homeowners, the most stressful part of renovation isn’t the noise, dust, or decisions. It’s the uncertainty. When will permits be approved? What inspections are required? Who’s handling what? For Charles Wierdsma Colorado, those questions aren’t secondary—they’re the root of most renovation delays. Through Sara Bay Construction LLC, he’s built a process that treats permitting and documentation not as afterthoughts, but as the foundation for predictable renovation outcomes.
“People don’t realize how much permitting shapes the timeline,” says Wierdsma. “It affects everything—when we start, what we schedule, even how the project gets designed in the first place.”
The Hidden Impact of Permitting on Project Timelines
Permitting delays are one of the leading causes of stalled renovation projects. A 2023 report from the National Association of Home Builders found that the average permitting delay for residential remodels in high-demand regions can range from two to six weeks, depending on the scope and municipality. In Sarasota, Florida, where permitting standards are strict and multi-unit buildings require layered approvals, the impact is even greater.
Wierdsma has seen it firsthand. Projects without permitting foresight often fall into a reactive cycle: redesigns triggered by missed code requirements, resubmittals due to incomplete documents, or inspections that halt work because sequencing didn’t align.
To prevent this, he front-loads the entire permitting process. Before any demolition or construction begins, he confirms:
-
Permit categories and thresholds based on project type
-
Required documentation and drawings
-
Known reviewer turnaround times
-
Specific inspection checkpoints tied to project phases
This proactive approach helps clients avoid the false starts and mid-project standstills that cost time and money.
How Documentation Creates Clarity for Everyone
Beyond permitting, documentation plays a crucial role in how Wierdsma reduces risk and builds trust. Clear, detailed documentation ensures that the homeowner, builder, subcontractors, inspectors, and city reviewers all work from the same playbook.
“It’s not about red tape,” he explains. “It’s about clarity. When documents are clean, decisions get made faster, expectations are aligned, and nobody has to guess.”
Each project begins with a fully defined scope of work, line-item estimates, and visual documentation when needed—especially in condo buildings or regulated structures where fire ratings, load-bearing walls, and mechanical systems trigger deeper reviews.
He also maintains digital access to key documents for clients and partners, including:
-
Permit applications and approvals
-
Engineering letters and plans
-
Inspection schedules and outcomes
-
Change orders with impact summaries
This centralized transparency reduces finger-pointing, keeps the project moving, and ensures that no detail gets lost between site visits.
Renovation Projects with Structural or Regulatory Complexity
Wierdsma specializes in condominium renovations, where city codes, HOA rules, and building limitations often collide. Many of these projects involve structural modifications, shared utility systems, or access restrictions that complicate typical workflows.
According to Sarasota County guidelines, structural changes in condos often require sealed engineering plans, multiple inspections, and coordinated access with building managers. A missed requirement can delay work by weeks.
Wierdsma navigates this by:
-
Engaging structural engineers early
-
Creating permit-ready documentation packages
-
Coordinating inspections in alignment with construction sequencing
-
Preparing building access plans and resident notices in advance
This level of planning not only keeps the project compliant—it protects the client from unnecessary disruption and potential fines.
One Homeowner’s Experience
A Sarasota homeowner who recently worked with Wierdsma on a full-unit condo renovation described the process as “the smoothest construction project I’ve ever experienced.” She added, “Every step was documented. Charles handled the permits, communicated with the HOA, and made sure the inspections didn’t slow anything down.”
That kind of outcome doesn’t happen by chance. It’s the result of structure.
Why Permitting and Documentation Should Never Be an Afterthought
Many builders treat permitting as a box to check once design decisions are made. Wierdsma flips that sequence. For him, permitting is part of the design process. He works with clients to align vision with what’s allowable and what’s realistic—especially when city codes, structural conditions, or building systems create limitations.
He also encourages clients to view documentation as a long-term asset. When renovations are well documented, resale becomes easier, future improvements are simpler, and warranty questions are clearer.
“Documentation isn’t paperwork—it’s a risk management tool,” he says. “And it’s one of the easiest ways to prevent problems later.”
A Renovation Philosophy Built on Structure and Respect
For Charles Wierdsma Colorado, renovation success depends on more than design or craftsmanship. It depends on structure. That includes:
-
Starting with regulatory research
-
Documenting every major decision
-
Sequencing work in alignment with inspections
-
Communicating clearly across all stakeholders
In a market where renovations often come with headaches, Wierdsma offers a different experience—one rooted in planning, guided by discipline, and structured to reduce risk.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Rask AI Expands Global Content Localization Capabilities With Integrated AI Tool Suite for 2026
Dover, Delaware, United States, 14th Jan 2026 – Rask AI, a provider of AI-powered content localization technology, announced continued expansion of its platform as organizations increasingly seek scalable solutions to adapt video and audio content for global audiences. The company’s integrated toolset enables businesses, media organizations, and educators to translate, dub, subtitle, and localize content across more than 130 languages using automation.
As demand grows for multilingual content distribution without the cost of re-production, Rask AI reports rising adoption of its modular localization tools designed to support video, audio, and text workflows within a single platform.
Integrated Tools Supporting Global Content Strategies
Rask AI’s platform brings together six core tools that address the full lifecycle of content localization, allowing organizations to repurpose existing assets for international markets.
The Rask AI Video Translator enables automated transcription, translation, dubbing, and subtitle generation for video content. The tool supports multi-speaker detection, optional voice cloning, and lip synchronization to preserve consistency across translated versions.
The Rask AI Audio Translator extends these capabilities to audio-only formats such as podcasts, webinars, and recorded briefings. It supports long-form audio translation, editable transcripts, and export options for downstream publishing and archiving workflows.
For creators and brands managing content libraries on YouTube, Rask AI’s YouTube Transcription Tool allows direct URL-based transcription and translation, enabling captions and scripts to be generated without manual file handling.
Preserving Voice Identity and Visual Alignment
Rask AI also offers Voice Cloning technology, allowing speakers to retain their vocal identity across multiple languages. This capability is designed for executives, educators, and on-camera hosts whose voice is closely associated with brand recognition.
To enhance realism in translated video content, Rask AI Lip Sync adjusts mouth movements to align with translated audio. This feature is intended for interviews, educational content, and long-form video where visual credibility is essential.
The platform’s Subtitle Generation Tool supports automated captioning, translation, and styling across formats and platforms. Subtitles can be exported in standard formats or embedded directly into video files, supporting accessibility and discoverability requirements.
Modular Platform Designed for Scale
According to Rask AI, the platform is increasingly used as part of broader content, marketing, and education technology stacks. The tools are accessible through a web-based interface and APIs, allowing organizations to automate recurring localization tasks and integrate translation workflows into existing systems.
By enabling a single source asset to be converted into multiple localized formats, Rask AI positions its technology as infrastructure for global content distribution rather than a standalone translation utility.
About Rask AI
Rask AI is a U.S.-based technology company providing AI-driven localization tools for video, audio, and text content. The platform supports transcription, translation, dubbing, voice cloning, lip synchronization, and subtitle generation across more than 130 languages.
Media Contact
Organization: Rask AI
Contact Person: Maria Chmir
Website: https://www.rask.ai/
Email:
info@rask.ai
Address:8 The Green, Suite A, Dover, Delaware 19901, USA
Country:United States
Release id:40170
The post Rask AI Expands Global Content Localization Capabilities With Integrated AI Tool Suite for 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Charles Wierdsma of Colorado | How Structured Project Management Creates Predictable Custom Home Outcomes
Sarasota, Florida, 14th January 2026, ZEX PR WIRE, In the world of residential construction, few issues frustrate homeowners more than delays, unclear expectations, or last-minute surprises. For Charles Wierdsma of Colorado, these aren’t just pain points—they’re symptoms of poor structure. As founder of Sara Bay Construction LLC in Sarasota, he has built his entire process around one core belief: predictable outcomes require structured project management.
With a background in information systems and construction technology, Wierdsma isn’t a traditional builder. His workflow reflects years spent managing IT infrastructure, installing renewable energy systems, and coordinating complex construction efforts where timing, scope, and communication had to align.
Today, his clients benefit from that experience through custom home builds and condominium renovations that feel less like chaos—and more like a system.
Building Predictability Through Planning
“Most stress in construction comes from uncertainty,” says Wierdsma. “If the homeowner doesn’t know what’s next or why something is delayed, the whole experience becomes frustrating. That’s avoidable.”
His process starts with what he calls a “definition phase,” where project scope, exclusions, decision timelines, and milestone sequences are clearly mapped out. That includes:
-
Detailed scopes of work
-
Allowance breakdowns for materials and finishes
-
A realistic project timeline with key homeowner decision points
-
Clarity on permitting lead times, inspections, and regulatory constraints
By front-loading this planning, Sara Bay Construction prevents the common pitfalls that derail projects midway.
According to a 2022 survey by the Joint Center for Housing Studies at Harvard, nearly 40% of homeowners report being dissatisfied with how construction timelines are communicated. Wierdsma’s structured workflows directly address this gap by making each step visible before construction even begins.
Sequencing as a Project Management Tool
Much of Wierdsma’s approach is rooted in sequencing—a principle he began applying while working in IT and solar installations. In both fields, every task depends on the one before it. If a system isn’t properly sequenced, progress stalls.
Construction is no different. Framing must come before electrical. Drywall can’t go up until inspections are complete. Materials must arrive in order—not in piles waiting to be installed.
“Poor sequencing wastes time and money,” he says. “It’s not just about what gets done, it’s about when and in what order.”
To ensure smooth execution, Wierdsma builds each project around task dependencies. Homeowners receive milestone outlines that explain why certain decisions—like tile selections or lighting layouts—are needed weeks before installation begins. This prevents material delays, trade conflicts, and rushed decisions.
Permitting: The Often-Ignored Risk Factor
One of the most overlooked aspects of residential construction is permitting. Wierdsma takes it seriously.
Sarasota and the surrounding Gulf Coast enforce strict permitting timelines and inspection windows, especially for structural renovations or multifamily units. Missing a submittal window or misjudging review duration can delay a project by weeks.
Wierdsma mitigates this by incorporating permitting lead times into the initial project schedule and confirming code requirements during the design phase. It’s a proactive stance that protects homeowners from frustrating slowdowns.
A 2021 NAHB report found that permitting issues account for up to 19% of residential construction delays. For Wierdsma, reducing this risk is a matter of discipline, not luck.
Communication as a Construction Deliverable
Clients who work with Charles Wierdsma Colorado often cite communication as one of his defining traits.
He doesn’t wait for homeowners to ask questions—he anticipates them. Regular check-ins, clearly documented scopes, and timely reminders about upcoming decisions help clients feel informed without being overwhelmed.
“It’s easier to trust the process when you understand it,” says Wierdsma. “Homeowners don’t want hand-holding—they want visibility.”
This mindset is reflected in every part of the process, from proposal reviews to walkthroughs. It also shows up in the way he handles changes. When a client wants to adjust scope or materials, Wierdsma explains how the change affects cost, timing, and sequence before moving forward.
That clarity creates confidence—and fewer surprises.
One Builder, Many Disciplines
Wierdsma’s structured style didn’t come from a traditional construction background alone. His years in technology taught him systems thinking. His time in solar taught him how to navigate permitting and work with multiple stakeholders. His community projects in Colorado sharpened his ability to coordinate people, tools, and timelines with care.
Those experiences now serve his Sarasota clients in a construction market where predictability is rare.
A Reliable Path Forward
Residential building will always involve variables—weather, material availability, inspection timing. But for Charles Wierdsma Colorado, the goal isn’t perfection. It’s predictability.
“When a homeowner chooses to build or renovate, they’re making a huge commitment,” he says. “They deserve a process that makes them feel supported, informed, and in control.”
Through structured planning, thoughtful sequencing, and steady communication, Wierdsma has created more than a construction company. He’s created a process designed to reduce stress, increase clarity, and deliver the kind of experience every homeowner wants—but few expect.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Boosting City Development With A Robust Convention & Exhibition Industry Suzhou International Expo Centre Writes A New Chapter In High-Quality Development
-
Press Release4 days ago
Finance Complaint List Issues Advisory Against Prevalent Elon Musk AI Deepfake Scams, Urges Public to Report Fraud to FBI, SEC, FTC, and FinanceComplaintList.com
-
Press Release1 week ago
KeyCrew Media Selects Steve Luther and CHORD Real Estate as Verified Expert for International Real Estate Investment and Panama Market Opportunities
-
Press Release5 days ago
Chainary Pro Launches Institutional-Grade Polymarket Trading Bot to Revolutionize Predictive Asset Management
-
Press Release5 days ago
Sandromeda Music Services Expands School-Safe Prom Entertainment Across Michigan
-
Press Release1 week ago
Martal Group Expands Its Leadership in B2B Lead Generation Across the United States with AI-Powered Sales Solutions
-
Press Release4 days ago
Public Interest Bulletin What Consumers Should Know About Justice Trace Services
-
Press Release4 days ago
Crown Business Academy, KRONEX, and Global Equity Capital: Building a Modern Trading and Education Ecosystem
